1432445-15-2
1432445-15-2 structure
- Name: NADH-IN-1
- Chemical Name: NADH-IN-1
- CAS Number: 1432445-15-2
- Molecular Formula: C19H21F3N2OS
- Molecular Weight: 382.44
- Catalog: Research Areas Metabolic Disease
- Create Date: 2022-08-20 09:12:05
- Modify Date: 2024-01-16 12:24:35
-
NADH-IN-1 has NADH:ubiquinone oxidoreductase inhibitory activity with an IC50 value of 27 μM. NADH-IN-1 can effectively stimulate glucose uptake in vitro. NADH-IN-1 is readily metabolised by the liver. NADH-IN-1 can be used for researching diabetes[1].
| Name | NADH-IN-1 |
|---|
| Description | NADH-IN-1 has NADH:ubiquinone oxidoreductase inhibitory activity with an IC50 value of 27 μM. NADH-IN-1 can effectively stimulate glucose uptake in vitro. NADH-IN-1 is readily metabolised by the liver. NADH-IN-1 can be used for researching diabetes[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 27 μM (NADH:ubiquinone oxidoreductase)[1] |
| In Vivo | NADH-IN-1 (1 μM) exhibits a short half-life and fast intrinsic clearance indicating that it is readily metabolised by the liver in vivo; shows no adverse effects on primary rat hepatocytes, and does not inhibit the hERG channel[1]. NADH-IN-1 (10 mg/kg; IV or PO; single dosage) produces no observable toxic effects at 10 mg/kg by IV or PO; exhibits a short half-life and high plasma clearance; exhibits high mouse and human serum protein binding, as well as moderate bioavailability[1]. Animal Model: Male C57BL/6 mice[1] Dosage: 10 mg/kg Administration: IV or PO; single dosage (Pharmacokinetics Analysis) Result: Produced no observable toxic effects at 10 mg/kg by IV or PO; exhibited a short half-life of 0.45 h and high plasma clearance; exhibited high mouse and human serum protein binding, as well as moderate bioavailability (21.4%). |
| References |
| Molecular Formula | C19H21F3N2OS |
|---|---|
| Molecular Weight | 382.44 |